Varfarex tab. of 5 mg No. 100

Varfarex – antitrombotichesky means.

Indications

• prevention and treatment of a deep vein thrombosis and embolism of a pulmonary artery;
• secondary prevention of a myocardial infarction and prevention of tromboembolic episodes (stroke or a system embolism) after a myocardial infarction;
• prevention of tromboembolic episodes at patients with fibrillation of an auricle, damage of heart valves or with the fitted a prosthesis heart valves;
• prevention of the fast-taking place ischemic attacks and a stroke.

Structure

• active ingredient: warfarin;
• 1 tablet contains 5 mg of the varfarinat of sodium (in the form of sodium of the varfarinat of a clathrate);
• other components: lactose, monohydrate; microcrystalline cellulose; krospovidon; magnesium stearate; indigo carmine (E 132) (for tablets of 3 mg) and crimson 4R (E 124) (for tablets of 5 mg).

Contraindication

• hypersensitivity to warfarin and/or any excipient of drug;
• clinically established bleeding;
• tendency to bleedings (angiohemophilia, hemophilia, thrombocytopenia and disturbance of functions of thrombocytes);
• in order to avoid risk of developing heavy bleedings within 72 hours after extensive surgeries, within 48 hours in a puerperal period;
• heavy renal and liver failure or cirrhosis;
• uncured or uncontrollable arterial hypertension;
• recent intracranial bleeding; the states leading to intracranial bleeding, for example aneurysm of brain arteries, an aortic aneurysm;
• tendency to a faint (falling);
• gastrointestinal or renal bleedings and their complications;
• divertuculosis;
• malignant tumors;
• gullet varicosity;
• infectious endocarditis, pericarditis or exudative pericarditis;
• a state at which therapy cannot be carried out rather safely (for example, dementia, psychosis, alcoholism);
• lumbar puncture.

Side reactions

from nervous system: subdural hematoma, fever.

from a blood and haematogenic system: a hemorrhage, coumarinic necrosis, a color of toes in purple color, a purpura, an eosinophilia, a vasculitis, anemia, decrease in a hematocrit.

from a respiratory system, a thorax and mediastinum: calcification of a trachea, hemothorax.

from digestive tract: nausea, vomiting, vomiting blood, diarrhea, pains in a stomach, gastrointestinal bleeding, bleeding from a rectum, a hammer.

from a gepatobiliarny system: reversible increase in activity of enzymes of a liver, cholestatic hepatitis, jaundice.

from skin and hypodermic fabric: a reversible alopecia, rash, urticaria, an itching, eczema, an erythematic cutaneous dropsy that leads to an ecchymoma, a heart attack and necrosis of skin.

from an urinogenital system: hamaturia, priapism.

General: allergic reactions (usually in the form of an enanthesis), nephrite, an urolithiasis, tubular necrosis.

Route of administration

Varfarex needs to be applied at the same time.

Varfarex's Dose is defined by the doctor for each patient individually, being guided by prothrombin MNV indicators.

Range of target MNO at therapy by oral anticoagulants.

Prevention of tromboembolic episodes at patients with the fitted a prosthesis heart valves: MNO – 2.5-3.5. Other indications: MNO – 2.0-3.0.

Adult. Patients with the normal body weight and initial MNO lower than 1.2 should apply 10 mg/days of warfarin (2 tablets on 5 mg) within 3 days. The subsequent doses, in view of the MNO level for the 4th day.

Recommended initial dose for ambulatory patients and patients with congenital deficit With or S proteins makes 5 mg/days of warfarin within 3 days. The subsequent doses, in view of the MNO level for the 4th day.

Feature of use

Indispensable condition of therapy by Varfarex is strict observance of reception of the appointed medicament dose.

Use during pregnancy or feeding by a breast

Drug is contraindicated to pregnant women in connection with its teratogenic action, a possibility of development of bleedings in a fruit and its death. The danger of intake of warfarin to a fruit should be estimated carefully risk for mother in case of warfarin non-use. Antitrombotichesky therapy during pregnancy should be carried out individually under careful observation of the corresponding experts.

Warfarin gets into breast milk in insignificant quantity and almost does not affect blood clotting at the child therefore medicament can be used during feeding by a breast.

by

on appointment and under observation of pediatricians.

Ability to influence speed of response at control of motor transport or other mechanisms

3 mg and 5 mg do not affect ability to run motor transport or to serve mechanisms.

Overdose

Symptoms: bleedings, bleeding.

Treatment: in mild cases at gradual overdose it is usually enough to lower a dose or to stop treatment by warfarin before return of MNO to target level. At acute overdose of medicament the gastric emptying is not recommended because of risk of developing of bleeding. It is necessary to apply activated carbon to prevention of absorption and enterogepatichesky recirculation of warfarin repeatedly. At use of activated carbon parenterally (in / c) it is necessary to enter vitamin K. At development of bleeding it is necessary to terminate warfarin, applying vitamin K (intravenously in a dose of 5-10 mg), a concentrate of a factor of coagulation or the fresh frozen plasma. In need of further anti-coagulation it is necessary to avoid use of vitamin K in a dose more than 10 mg. Otherwise the patient can be Warfarin, resistant to therapy, within 2 weeks.

to Store

in the place protected from light at a temperature not above 25 °C.

to Store

out of children's reach.